Coherus biosciences, inc. (CHRS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue:
Total revenue

116,200

123,854

111,684

83,433

37,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration and license revenue

-

-

-

-

-

-

-

-

-

-

0

1,395

161

-

162,835

14,068

12,359

10,198

7,167

6,866

5,810

5,761

16,052

4,965

3,596

506

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,866

5,810

-

-

-

-

-

Operating expenses:
Cost of goods sold

6,855

7,805

6,447

601

2,225

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

33,107

34,948

21,568

18,883

18,789

26,662

31,603

26,519

25,455

31,488

42,626

34,500

53,775

59,010

64,573

65,544

65,313

51,433

68,218

56,944

36,467

26,867

18,496

18,925

13,936

4,934

Selling, general and administrative

35,350

36,070

31,828

36,456

32,683

33,840

25,369

18,391

16,577

14,978

13,989

23,533

18,803

15,294

13,645

11,260

11,398

10,972

10,166

8,817

6,091

6,186

3,979

3,978

3,421

2,355

Total operating expenses

75,312

78,823

59,843

55,940

53,697

60,502

56,972

44,910

42,032

46,466

56,615

58,033

72,578

74,304

78,218

76,804

76,711

62,405

78,384

65,761

42,558

33,053

22,475

22,903

17,357

7,289

Income (loss) from operations

40,868

45,033

51,841

27,493

-16,599

-60,502

-56,972

-44,910

-42,032

-46,466

-56,615

-56,638

-72,417

-73,460

84,617

-62,736

-64,352

-52,207

-71,217

-58,895

-36,748

-26,560

-6,423

-17,938

-13,761

-6,783

Interest expense (includes related party of $620 and $610 for the three months ended March 31, 2020 and 2019, respectively)

4,431

4,483

4,469

4,433

4,216

2,434

2,425

2,417

2,408

2,400

2,392

2,384

2,376

2,369

2,420

2,354

837

-

33

-

-

0

1

1,158

2,741

1,992

Other income, net

68

721

518

558

811

340

571

3,642

138

-203

14

3,620

-29

-115

1,647

-5,060

-349

-373

-235

-139

-4,091

-2,463

-1,490

-5,974

-8,668

-12,698

Net income (loss) before income taxes

36,505

41,271

47,890

23,618

-20,004

-

-58,826

-43,685

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax provision

900

2,002

847

51

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

35,600

39,227

47,043

23,567

-20,004

-62,596

-58,826

-43,685

-44,302

-49,069

-58,993

-55,402

-74,822

-75,944

83,844

-70,150

-65,538

-52,580

-71,485

-59,034

-40,839

-29,023

-7,914

-25,070

-25,170

-21,473

Net loss attributable to non-controlling interest

-

-

0

0

-

0

-18

-47

-5

-2

-4

-66

-44

-23

-95

-183

-150

-189

-151

-224

-114

-

-42

-113

-

-

Net income (loss)

35,572

39,227

47,043

23,567

-20,004

-62,596

-58,808

-43,638

-44,297

-49,067

-58,989

-55,336

-74,778

-75,921

83,939

-69,967

-65,388

-52,391

-71,334

-58,810

-40,725

-29,134

-7,872

-24,957

-25,170

-21,473

Net loss per share attributable to Coherus, basic and diluted

-

-

-

-

-

-

-

-

-0.74

-

-1.09

-1.08

-1.54

-

-

-1.72

-1.67

-

-

-1.56

-1.22

3.14

-1.79

-5.96

-6.03

-6.23

Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted

-

-

-

-

-

-

-

-

60,122

-

54,070

51,291

48,711

-

-

40,698

39,095

-

-

37,672

33,377

19,972

4,409

4,186

4,177

3,444

Net income (loss) per share:
Basic

0.50

0.57

0.67

0.34

-0.29

-

-0.87

-0.68

-

-

-

-

-

-

1.93

-

-

-

-1.86

-

-

-

-

-

-

-

Diluted

0.48

0.57

0.63

0.32

-0.29

-

-0.87

-0.68

-

-

-

-

-

-

1.67

-

-

-

-1.86

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net income (loss) per share:
Basic

70,662

70,222

69,877

69,479

69,140

-

67,848

63,960

-

-

-

-

-

-

43,469

-

-

-

38,426

-

-

-

-

-

-

-

Diluted

74,416

72,108

78,530

72,963

69,140

-

67,848

63,960

-

-

-

-

-

-

51,581

-

-

-

38,426

-

-

-

-

-

-

-